Oral vinorelbine: Feasibility and safety profile

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1677-1681

  Depierre, A ^a   Freyer, G ^b   Jassem, J ^c   Orfeuvre, H ^d   Ramlau, R ^e   Lemarie, E ^f   Koralewski, P ^g   Mauriac, L ^h   Breton, J L ⁱ   Delozier, T ^j   Trillet Lenoir, V ^b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ LYON 1   (France)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d Department of Medical Oncology   (France)

^e Hospital of Lung Diseases   (Poland)

^f CHU BRETONNEAU   (France)

^g Ludwik Rydygier Speciality Hospital in Krakow   (Poland)

^h INSTITUT BERGONIÉ   (France)

ⁱ HÔPITAL DU BOCAGE   (France)

^j CENTRE FRANÇOIS BACLESSE   (France)

more..

Author keywords

Advanced breast cancer; Non small cell lung cancer; Oral vinorelbine; Safety profile

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; METOCLOPRAMIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER MORTALITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; ESOPHAGITIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STOMATITIS;

EID: 20244388921     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013567022670     Document Type: Article

References (16)

1. A Phase II study of vinorelbine in the treatment of non-small-cell lung cancer
2. Vinorelbine vs. vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A randomized trial
3. Randomized study of vinorelbine and cisplatin vs. vindesine and cisplatin vs. vinorelbine alone in advanced non-small-cell lung cancer. Results of a European multicenter trial including 612 patients
4. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
5. Patient preference for oral vs. intravenous palliative chemotherapy
6. Oral chemotherapy: Rationale and future directions
7. Phase I trial of oral vinorelbine in patients with advanced breast cancer
8. Absolute bioavailability and pharmacokinetics of oral vinorelbine in patients with solid tumors
9. Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumors
10. Effects of food study on pharmacokinetics profile and safety of oral vinorelbine in patients with solid tumors or lymphomas
11. The outpatient management of febrile neutropenia in cancer patients
12. Support to phase II clinical trials of oral vinorelbine by population pharmacokinetics: A new tool to follow drug toxicities
13. A summary of vinorelbine (Navelbine) safety data from North American Clinical Trials
14. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
15. Randomized trial with vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV NSCLC
16. A multicenter randomised phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients